Mansfield Kathryn E, Nitsch Dorothea, Smeeth Liam, Bhaskaran Krishnan, Tomlinson Laurie A
Department of Non-Communicable Disease Epidemiology, London School of Hygiene and Tropical Medicine, London, UK.
BMJ Open. 2016 Dec 21;6(12):e012690. doi: 10.1136/bmjopen-2016-012690.
To investigate whether there is an association between use of ACE inhibitors (ACEI) and angiotensin receptor blockers (ARB) and risk of acute kidney injury (AKI).
We conducted a new-user cohort study of the rate of AKI among users of common antihypertensives.
UK primary care practices contributing to the Clinical Practice Research Datalink (CPRD) eligible for linkage to hospital records data from the Hospital Episode Statistics (HES) database between April 1997 and March 2014.
New users of antihypertensives: ACEI/ARB, β-blockers, calcium channel blockers and thiazide diuretics.
The outcome was first episode of AKI. We estimated incidence rate ratio (RR) for AKI during time exposed to ACEI/ARB compared to time unexposed, adjusting for age, sex, comorbidities, use of other antihypertensive drugs and calendar period using Poisson regression. Covariates were time updated.
Among 570 445 participants, 303 761 were prescribed ACEI/ARB with a mean follow-up of 4.1 years. The adjusted RR of AKI during time exposed to ACEI/ARB compared to time unexposed was 1.12 (95% CI 1.07 to 1.17). This relative risk varied depending on absolute risk of AKI, with lower or no increased relative risk from the drugs among those at greatest absolute risk. For example, among people with stage 4 chronic kidney disease (who had 6.69 (95% CI 5.57 to 8.03) times higher rate of AKI compared to those without chronic kidney disease), the adjusted RR of AKI during time exposed to ACEI/ARB compared to time unexposed was 0.66 (95% CI 0.44 to 0.97) in contrast to 1.17 (95% CI 1.09 to 1.25) among people without chronic kidney disease.
Treatment with ACEI/ARB is associated with only a small increase in AKI risk while individual patient characteristics are much more strongly associated with the rate of AKI. The degree of increased risk varies between patient groups.
研究使用血管紧张素转换酶抑制剂(ACEI)和血管紧张素受体阻滞剂(ARB)与急性肾损伤(AKI)风险之间是否存在关联。
我们针对常用抗高血压药物使用者中的AKI发生率开展了一项新使用者队列研究。
英国基层医疗实践机构参与了临床实践研究数据链(CPRD),该数据链在1997年4月至2014年3月期间有资格与医院事件统计(HES)数据库中的医院记录数据相链接。
抗高血压药物新使用者:ACEI/ARB、β受体阻滞剂、钙通道阻滞剂和噻嗪类利尿剂。
研究结果为首次发生AKI。我们通过泊松回归分析,估计了暴露于ACEI/ARB期间与未暴露期间AKI的发病率比值比(RR),并对年龄、性别、合并症、其他抗高血压药物的使用情况以及日历时间进行了调整。协变量随时间更新。
在570445名参与者中,303761人被处方使用ACEI/ARB,平均随访4.1年。与未暴露期间相比,暴露于ACEI/ARB期间AKI的调整后RR为1.12(95%CI 1.07至1.17)。这种相对风险因AKI的绝对风险而异,在绝对风险最高的人群中,这些药物导致的相对风险较低或没有增加。例如,在4期慢性肾病患者中(其AKI发生率比无慢性肾病患者高6.69倍(95%CI 5.57至8.